## First Quarter 2018 Results

Supplementary Data

## Table of Contents

Page

1. Segment Information by Business Unit. ..... P 1
2. Other Income ..... P 1
3. Net Sales by Region \& Business Unit. ..... P 2
4. Statements of Cash Flows ..... P 2
5. Foreign Exchange Rate Impact ..... P 3
6. Sales Growth on a Local Currency Basis (Year over Year) ..... P 3
7. Net Sales Growth Rate of Hardware \& Non-hardware. ..... P 4
8. Color Ratio (MFDs \& LPs) ..... P 4
9. Sales Growth by Monochrome \& Color MFDs ..... P 4
10. Interchangeable Lens Digital Camera Ratio ..... P 4
11. IC Stepper Unit Breakdown by Light Source ..... P 4
12. R\&D Expenditure / Capex / Depreciation \& Amoritization. ..... P 5
13. Other Financial Data. ..... P 5


#### Abstract

This document contains forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertainties and reflect management's views and assumptions formed by available information. All statements other than statements of historical fact are statements that could be considered forward-looking statements. When used in this document, words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project" or "should" and similar expressions, as they relate to Canon, are intended to identify forward-looking statements. Many factors could cause the actual results, performance or achievements of Canon to be materially different from any future results, performance or achievements that may be expressed or implied by such forwardlooking statements, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, introduction of competing products by other companies, lack of acceptance of new products or services by Canon's targeted customers, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, both referenced and not referenced in this document. A detailed description of these and other risk factors is included in Canon's annual report on Form 20-F, which is on file with the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. Canon does not intend or assume any obligation to update these forwardlooking statements.


1. Segment Information by Business Unit

|  | FY 2017 |  | FY 2018 |  | \% Change Y/Y |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $1 \mathrm{Q}$ <br> Actual | Full Year <br> Actual | $1 \mathrm{Q}$ <br> Actual | Full Year <br> Projection | 1Q | Full Year |
| Office |  |  |  |  |  |  |
| External customers | 457,137 | 1,863,688 | 457,140 | 1,937,700 | +0.0\% | +4.0\% |
| Intersegment | 608 | 2,240 | 582 | 1,300 | -4.3\% | -42.0\% |
| Total sales | 457,745 | 1,865,928 | 457,722 | 1,939,000 | -0.0\% | +3.9\% |
| Operating profit | 55,428 | 180,648 | 53,043 | 235,500 | -4.3\% | +30.4\% |
| Operating profit ratio | 12.1\% | 9.7\% | 11.6\% | 12.1\% |  |  |
| Imaging System |  |  |  |  |  |  |
| External customers | 241,900 | 1,135,584 | 221,642 | 1,152,000 | -8.4\% | +1.4\% |
| Intersegment | 159 | 604 | 157 | 1,000 | -1.3\% | +65.6\% |
| Total sales | 242,059 | 1,136,188 | 221,799 | 1,153,000 | -8.4\% | +1.5\% |
| Operating profit | 29,236 | 175,913 | 24,707 | 193,000 | -15.5\% | +9.7\% |
| Operating profit ratio | 12.1\% | 15.5\% | 11.1\% | 16.7\% |  |  |
| Medical System |  |  |  |  |  |  |
| External customers | 131,624 | 434,985 | 117,025 | 469,600 | -11.1\% | +8.0\% |
| Intersegment | 131 | 1,202 | 40 | 400 | -69.5\% | -66.7\% |
| Total sales | 131,755 | 436,187 | 117,065 | 470,000 | -11.1\% | +7.8\% |
| Operating profit | 9,896 | 22,505 | 10,507 | 27,000 | +6.2\% | +20.0\% |
| Operating profit ratio | 7.5\% | 5.2\% | 9.0\% | 5.7\% |  |  |
| Industry \& Others |  |  |  |  |  |  |
| External customers | 142,100 | 645,758 | 164,905 | 740,700 | +16.0\% | +14.7\% |
| Intersegment | 20,360 | 85,946 | 23,643 | 98,300 | +16.1\% | +14.4\% |
| Total sales | 162,460 | 731,704 | 188,548 | 839,000 | +16.1\% | +14.7\% |
| Operating profit | 8,707 | 56,788 | 18,598 | 69,400 | +113.6\% | +22.2\% |
| Operating profit ratio | 5.4\% | 7.8\% | 9.9\% | 8.3\% |  |  |
| Corporate \& Eliminations |  |  |  |  |  |  |
| External customers | - | - | - | - | - | - |
| Intersegment | -21,258 | -89,992 | -24,422 | -101,000 | - | - |
| Total sales | -21,258 | -89,992 | -24,422 | -101,000 | - | - |
| Operating profit Operating profit ratio | -30,077 | -114,249 | -29,772 | -120,900 | - | - |
| Consolidated |  |  |  |  |  |  |
| External customers | 972,761 | 4,080,015 | 960,712 | 4,300,000 | -1.2\% | +5.4\% |
| Intersegment | - | - | - | - | - | - |
| Total sales | 972,761 | 4,080,015 | 960,712 | 4,300,000 | -1.2\% | +5.4\% |
| Operating profit | 73,190 | 321,605 | 77,083 | 404,000 | +5.3\% | +25.6\% |
| Operating profit ratio | 7.5\% | 7.9\% | 8.0\% | 9.4\% |  |  |

## 2. Other Income

|  | FY 2017 |  | FY 2018 |  |
| :--- | ---: | ---: | ---: | ---: |
|  | 1 Q | Full Year | 1Q | Full Year |
|  | Actual | Actual | Actual | Projection |
| Interest and dividend, net | 1,031 | 5,194 | 1,695 | 2,400 |
| FX gain (loss) | $-1,211$ | $-9,775$ | 413 | $-2,900$ |
| Equity earnings of affiliated cos. | 512 | 1,196 | 297 | 1,000 |
| Other, net | 4,488 | 35,664 | 6,271 | 15,500 |
| Total | 4,820 | 32,279 | 8,676 | 16,000 |


| (Millions of yen) |  |
| ---: | ---: |
| Amount Change Y/Y |  |
| 1 Q | Full Year |
| +664 | $-2,794$ |
| $+1,624$ | $+6,875$ |
| -215 | -196 |
| $+1,783$ | $-20,164$ |
| $+3,856$ | $-16,279$ |

[^0]3. Net Sales by Region \& Business Unit

|  | FY 2017 |  | FY 2018 |  | \% Change Y/Y |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \hline 1 \mathrm{Q} \\ \text { Actual } \end{gathered}$ | Full Year Actual | $\begin{gathered} \hline 1 \mathrm{Q} \\ \text { Actual } \end{gathered}$ | Full Year Projection | 1Q | Full Year |
| Japan |  |  |  |  |  |  |
| Office | 94,054 | 381,475 | 98,626 | - | +4.9\% | - |
| Imaging System | 32,611 | 174,944 | 28,401 | - | -12.9\% | - |
| Medical System | 70,141 | 190,276 | 56,018 | - | -20.1\% |  |
| Industry \& Others | 33,761 | 138,133 | 41,895 | - | +24.1\% |  |
| Total | 230,567 | 884,828 | 224,940 | 947,200 | -2.4\% | +7.0\% |
| Overseas |  |  |  |  |  |  |
| Office | 363,083 | 1,482,213 | 358,514 | - | -1.3\% | - |
| Imaging System | 209,289 | 960,640 | 193,241 | - | -7.7\% |  |
| Medical System | 61,483 | 244,709 | 61,007 | - | -0.8\% | - |
| Industry \& Others | 108,339 | 507,625 | 123,010 | - | +13.5\% | - |
| Total | 742,194 | 3,195,187 | 735,772 | 3,352,800 | -0.9\% | +4.9\% |
| Americas |  |  |  |  |  |  |
| Office | 146,339 | 602,376 | 139,089 | - | -5.0\% | - |
| Imaging System | 66,111 | 316,756 | 57,067 | - | -13.7\% | - |
| Medical System | 24,144 | 102,131 | 22,368 | - | -7.4\% |  |
| Industry \& Others | 19,279 | 86,252 | 21,087 | - | +9.4\% |  |
| Total | 255,873 | 1,107,515 | 239,611 | 1,147,300 | -6.4\% | +3.6\% |
| Europe |  |  |  |  |  |  |
| Office | 141,004 | 580,825 | 144,192 | - | +2.3\% | - |
| Imaging System | 66,556 | 301,906 | 63,462 | - | -4.6\% |  |
| Medical System | 18,289 | 80,035 | 23,006 | - | +25.8\% | - |
| Industry \& Others | 15,723 | 65,649 | 17,189 | - | +9.3\% | - |
| Total | 241,572 | 1,028,415 | 247,849 | 1,101,700 | +2.6\% | +7.1\% |
| Asia \& Oceania |  |  |  |  |  |  |
| Office | 75,740 | 299,012 | 75,233 | - | -0.7\% | - |
| Imaging System | 76,622 | 341,978 | 72,712 | - | -5.1\% | - |
| Medical System | 19,050 | 62,543 | 15,633 | - | -17.9\% | - |
| Industry \& Others | 73,337 | 355,724 | 84,734 | - | +15.5\% | - |
| Total | 244,749 | 1,059,257 | 248,312 | 1,103,800 | +1.5\% | +4.2\% |
| Intersegment |  |  |  |  |  |  |
| Office | 608 | 2,240 | 582 | - | -4.3\% | - |
| Imaging System | 159 | 604 | 157 | - | -1.3\% | - |
| Medical System | 131 | 1,202 | 40 | - | -69.5\% | - |
| Industry \& Others | 20,360 | 85,946 | 23,643 | - | +16.1\% | - |
| Eliminations | -21,258 | -89,992 | -24,422 | - | - | - |
| Total | 0 | 0 | 0 | 0 | - | - |
| Total |  |  |  |  |  |  |
| Office | 457,745 | 1,865,928 | 457,722 | - | -0.0\% | - |
| Imaging System | 242,059 | 1,136,188 | 221,799 | - | -8.4\% | - |
| Medical System | 131,755 | 436,187 | 117,065 | - | -11.1\% | - |
| Industry \& Others | 162,460 | 731,704 | 188,548 | - | +16.1\% |  |
| Eliminations | -21,258 | -89,992 | -24,422 | - | - | - |
| Total | 972,761 | 4,080,015 | 960,712 | 4,300,000 | -1.2\% | +5.4\% |

4. Statements of Cash Flows

|  | FY 2017 |  | FY 2018 |  |
| :--- | ---: | ---: | ---: | ---: |
|  | $1 Q$ <br> Actual | Full Year <br> Actual | $1 Q$ <br> Actual | Full Year <br> Projection |
|  | 167,421 | 590,557 | 42,143 | 550,000 |
| Net cash used in investing activities | $-50,096$ | $-165,010$ | $-49,921$ | $-330,000$ |
| Free cash flow | 117,325 | 425,547 | $-7,778$ | 220,000 |
| Net cash provided by (used in) financing activities | $-83,446$ | $-340,464$ | $-95,721$ | $-321,800$ |
| Effect of exchange rate changes on cash and cash equivalents | $-9,418$ | 6,538 | $-17,604$ | $-10,000$ |
| Net change in cash and cash equivalents | 24,461 | 91,621 | $-121,103$ | $-111,800$ |
| Cash and cash equivalents at end of period | 654,654 | 721,814 | 600,711 | 610,000 |

(Millions of yen)

| Amount Change $\mathrm{Y} / \mathrm{Y}$ |  |
| ---: | ---: |
| 1 y | Full Year |
| $-125,278$ | $-40,557$ |
| +175 | $-164,990$ |
| $-125,103$ | $-205,547$ |
| $-12,275$ | $+18,664$ |
| $-8,186$ | $-16,538$ |
| $-145,564$ | $-203,421$ |
| $-53,943$ | $-111,814$ |

## 5. Foreign Exchange Rate Impact

## (1) Exchange rates

|  | FY 2017 |  | FY 2018 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q Actual | Full Year Actual | 1Q Actual | $2 Q-4 Q$ <br> Projection | Full Year Projection |
| USD/Yen | 113.53 | 112.13 | 108.03 | 107.00 | 107.24 |
| EUR/Yen | 121.03 | 126.69 | 133.10 | 132.00 | 132.25 |

(2) Amount of impact on net sales (Year over Year)

| (Billions of yen) |  |  |
| :--- | ---: | ---: |
|  | FY 2018 |  |
|  | 1Q | Full Year |
| EUR | -16.0 | Projection |
| Other currencies | +19.1 | -63.6 |
| Total | +1.2 | +38.8 |
|  | +4.3 | +1.9 |

(3) Impact of foreign exchange rate per yen

|  | (Billions of yen) |
| :--- | ---: |
|  | FY 2018 $-4 Q$ <br> Projection |
| On sales |  |
| USD | 11.2 |
| EUR | 5.1 |
| On operating Profit | 4.1 |
| USD | 2.5 |

## 6. Sales Growth on a Local Currency Basis (Year over Year)

|  | FY 2018 |  |
| :--- | ---: | ---: |
|  | 1Q <br> Actual | Full Year <br> Projection |
| Japan | $+4.9 \%$ | - |
| Overseas | $-1.5 \%$ | - |
| Total | $-0.2 \%$ | $+4.6 \%$ |
| Imaging System | $-12.9 \%$ | - |
| Japan | $-8.8 \%$ | - |
| Overseas | $-9.4 \%$ | $+2.0 \%$ |
| Total | $-20.1 \%$ | - |
| Medical System | $-2.0 \%$ | - |
| Japan | $-11.7 \%$ | $+8.4 \%$ |
| Overseas |  | - |
| Total | $+24.1 \%$ | - |
| Industry \& Others | $+13.4 \%$ | - |
| Japan | $+16.0 \%$ | $+14.8 \%$ |
| Overseas |  | - |
| Total | $-2.4 \%$ | - |
| Total | $-1.4 \%$ | - |
| Japan | $-2.1 \%$ | - |
| Overseas | $-4.6 \%$ | - |
| Asia and Oceania | $+2.3 \%$ | - |

7. Net Sales Growth Rate of Hardware \& Non-hardware

|  |  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1Q Actual | Full Year Actual | 1Q <br> Actual | Full Year Projection |
| MFDs |  |  |  |  |  |
| JPY | Hardware Non-hardware | $\begin{aligned} & \hline-2 \% \\ & -2 \% \\ & \hline \end{aligned}$ | $\begin{aligned} & +2 \% \\ & +3 \% \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline-5 \% \\ +2 \% \\ \hline \end{array}$ | $\begin{aligned} & +9 \% \\ & +1 \% \end{aligned}$ |
| LC | Hardware <br> Non-hardware | $\begin{aligned} & 0 \% \\ & 0 \% \\ & \hline \end{aligned}$ | $\begin{array}{r} \hline-2 \% \\ +1 \% \\ \hline \end{array}$ | $\begin{array}{r\|} \hline-6 \% \\ 0 \% \\ \hline \end{array}$ | $\begin{array}{r} +10 \% \\ +1 \% \end{array}$ |
| LPs |  |  |  |  |  |
| JPY | Hardware <br> Non-hardware | $\begin{array}{r} +12 \% \\ +4 \% \\ \hline \end{array}$ | $\begin{aligned} & +6 \% \\ & +6 \% \end{aligned}$ | $\begin{gathered} +2 \% \\ -4 \% \end{gathered}$ | 0\% |
| LC | Hardware <br> Non-hardware | $\begin{array}{r} +12 \% \\ +3 \% \\ \hline \end{array}$ | $\begin{aligned} & +3 \% \\ & +3 \% \\ & \hline \end{aligned}$ | $\begin{array}{c\|} \hline+3 \% \\ -2 \% \\ \hline \end{array}$ | $\begin{aligned} & +1 \% \\ & +2 \% \\ & \hline \end{aligned}$ |
| IJPs |  |  |  |  |  |
| JPY | Hardware <br> Non-hardware | $\begin{array}{r} \hline+11 \% \\ -6 \% \end{array}$ | $+11 \%$ $-2 \%$ | $-3 \%$ $-4 \%$ | +4\% $0 \%$ |
| LC | Hardware <br> Non-hardware | $\begin{array}{r}+14 \% \\ -4 \% \\ \hline\end{array}$ | $+8 \%$ $-5 \%$ | $-4 \%$ <br> $-5 \%$ | $\begin{array}{r}+5 \% \\ 0 \% \\ \hline\end{array}$ |

8. Color Ratio (MFDs \& LPs)

|  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 1Q <br> Actual | Full Year Actual | 1Q <br> Actual | Full Year Projection |
| MFDs |  |  |  |  |
| Net Sales QTY | 59\% $55 \%$ | 58\% $55 \%$ | 58\% $57 \%$ | 60\% $57 \%$ |
| LPs |  |  |  |  |
| Net Sales QTY | 50\% $16 \%$ | 52\% 18\% | 51\% 17\% | 53\% 19\% |

9. Sales Growth by Monochrome \& Color MFDs

|  |  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 1Q <br> Actual | Full Year Actual | 1Q <br> Actual | Full Year Projection |
| JPY | Monochrome Color | $-7 \%$ $+2 \%$ | $-1 \%$ $+5 \%$ | $-1 \%$ $-2 \%$ | $0 \%$ $+8 \%$ |
| LC | Monochrome Color | $-5 \%$ $+4 \%$ | $-3 \%$ $+2 \%$ | $-2 \%$ $-3 \%$ | $+1 \%$ $+8 \%$ |

## 10. Interchangeable Lens Digital Camera Ratio

|  | FY 2017 |  | FY 2018 |  |
| :---: | ---: | ---: | ---: | ---: |
|  | 1Q | Full Year | 1Q | Full Year |
|  | Actual | Actual | Actual | Projection |
| Value Base | $83 \%$ | $85 \%$ | $86 \%$ | $87 \%$ |
| Unit Base | $52 \%$ | $58 \%$ | $64 \%$ | $62 \%$ |

* Proportion of Total Digital Cameras
* Value Base Includes Interchangeable Lenses

11. IC Stepper Unit Breakdown by Light Source
(unit)

|  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 1Q <br> Actual | Full Year Actual | 1Q <br> Actual | Full Year Projection |
| KrF | 2 | 24 | 7 | 37 |
| i-Line | 9 | 46 | 20 | 89 |
| Total | 11 | 70 | 27 | 126 |

12. R\&D Expenditure / Capex / Depreciation \& Amoritization

|  | (Millions of yen) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | FY 2017 |  | FY 2018 |  |
|  | $\begin{gathered} 1 \mathrm{Q} \\ \text { Actual } \\ \hline \end{gathered}$ | Full Year <br> Actual | $\begin{gathered} \hline 1 Q \\ \text { Actual } \\ \hline \end{gathered}$ | Full Year Projection |
| R\&D Expenditure |  |  |  |  |
| Office | 22,248 | 91,763 | 24,767 | - |
| Imaging System | 21,838 | 91,784 | 20,033 |  |
| Medical System | 11,176 | 36,210 | 9,910 |  |
| Industry and Others | 16,177 | 68,131 | 15,794 |  |
| Corporate \& Eliminations | 10,655 | 45,483 | 8,416 | - |
| Total | 82,094 | 333,371 | 78,920 | 340,000 |
| \% of Net Sales | 8.4\% | 8.2\% | 8.2\% | 7.9\% |
| Capex | 31,638 | 147,542 | 32,993 | 200,000 |
| Depreciation \& Amoritization | 62,139 | 261,881 | 60,537 | 245,000 |

13.Other Financial Data

|  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $1 Q$ Actual | Full Year Actual | $1 \mathrm{Q}$ Actual | Full Year Projection |
| ROE * | 8.0\% | 8.6\% | 8.1\% | 9.6\% |
| ROA * | 4.3\% | 4.7\% | 4.5\% | 5.4\% |
| EPS (Yen) | 50.44 | 222.88 | 52.89 | 259.32 |
| Debt Ratio | 12.8\% | 10.2\% | 10.7\% |  |
| Number of Employees |  |  |  |  |
| Japan | 72,474 | 73,665 | 73,289 |  |
| Overseas | 125,000 | 124,111 | 124,829 |  |
| Total | 197,474 | 197,776 | 198,118 |  |
| Domestic Production Ratio | 65\% | 62\% | 62\% |  |

* Based on Net Income attributable to Canon Inc.

[^1]
[^0]:    * In 2018, a reclassification of operating profit and other income (deductions) was conducted due to change in pension accounting standard. 2017 figures were restated to conform with the current year's presentation.

[^1]:    * In 2018, a reclassification of operating profit and other income (deductions) was conducted due to change
    in pension accounting standard. 2017 figures were restated to conform with the current year's presentation

